Brokerages Set CryoLife Inc. (NYSE:CRY) Target Price at $15.25
CryoLife Inc. (NYSE:CRY) has been given a consensus recommendation of “Buy” by the six analysts that are currently covering the firm. One research analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $15.25.
Several equities analysts recently weighed in on CRY shares. Zacks Investment Research upgraded shares of CryoLife from a “hold” rating to a “strong-buy” rating and set a $18.00 price target on the stock in a report on Friday, August 12th. Lake Street Capital started coverage on shares of CryoLife in a report on Wednesday, June 15th. They issued a “buy” rating and a $15.00 price target on the stock. Canaccord Genuity reiterated a “buy” rating on shares of CryoLife in a report on Tuesday, July 26th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $16.00 price target on shares of CryoLife in a report on Wednesday, July 27th.
In other CryoLife news, Director C Elkins Ronald sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total value of $28,000.00. Following the sale, the director now owns 103,586 shares in the company, valued at approximately $1,450,204. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.08% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the company. Menta Capital LLC bought a new stake in CryoLife during the second quarter valued at approximately $133,000. Louisiana State Employees Retirement System raised its position in shares of CryoLife by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 11,400 shares of the company’s stock worth $135,000 after buying an additional 100 shares during the period. Arizona State Retirement System raised its position in shares of CryoLife by 5.7% in the first quarter. Arizona State Retirement System now owns 13,054 shares of the company’s stock worth $140,000 after buying an additional 700 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of CryoLife during the second quarter worth about $145,000. Finally, Thrivent Financial for Lutherans raised its position in shares of CryoLife by 6.7% in the second quarter. Thrivent Financial for Lutherans now owns 12,470 shares of the company’s stock worth $147,000 after buying an additional 780 shares during the period. Institutional investors and hedge funds own 58.13% of the company’s stock.
CryoLife (NYSE:CRY) opened at 17.41 on Tuesday. The company has a market capitalization of $593.86 million, a price-to-earnings ratio of 55.80 and a beta of 1.14. CryoLife has a 52 week low of $8.94 and a 52 week high of $18.64. The company has a 50 day moving average of $16.72 and a 200 day moving average of $13.18.
CryoLife (NYSE:CRY) last issued its quarterly earnings results on Monday, July 25th. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.11. CryoLife had a net margin of 5.80% and a return on equity of 8.15%. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $35.50 million. During the same quarter in the prior year, the company earned $0.03 EPS. CryoLife’s quarterly revenue was up 32.6% on a year-over-year basis. On average, equities analysts forecast that CryoLife will post $0.34 EPS for the current fiscal year.
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.